UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

UPCC 11417: A Phase 3  Multicenter  Randomized  Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Brief description of study

Request for collaborative review: WIRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myeloid Leukemia
  • Age: - 99 Years
  • Gender: All
Updated on 30 Jan 2020. Study ID: 827342

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center